Second allo-SCT in patients with lymphoma relapse after a first allogeneic transplantation. A retrospective study of the EBMT Lymphoma Working Party

Bone Marrow Transplantation
K HorstmannPeter Dreger

Abstract

The aim of this registry-based retrospective study was to analyze the outcome of second allogeneic hematopoietic SCT (alloHSCT_2) performed in patients with lymphoma who had relapsed after a first allogeneic transplant (alloHSCT_1). Patients ⩾18 years who had received an alloHSCT_2 for lymphoma relapse between 2000 and 2011 were eligible. One hundred and forty patients were identified. The diagnosis was Hodgkin lymphoma (HL) in 31%, diffuse large B-cell lymphoma in 14%, T-cell lymphoma in 12%, indolent lymphoma in 19%, mantle cell lymphoma in 16% and other lymphomas in 8% of the patients. The median interval from alloHSCT_1 to alloHSCT_2 was 19 (range 4-116) months. Disease status at alloHSCT_2 was chemosensitive in 46%, refractory in 43% and unknown in 11% of the patients. Three-year PFS, OS, relapse incidence and nonrelapse mortality were 19%, 29%, 58% and 23%, respectively. PFS and OS were significantly affected by refractory disease at alloHSCT_2 and a short interval between alloHSCT_1 and alloHSCT_2. Long-term PFS was observed across all lymphoma subsets except for aggressive B-cell lymphoma. In conclusion, alloHSCT_2 is feasible and can result in long-term disease control in patients with lymphoma recurrence after alloHSC...Continue Reading

References

Nov 2, 2004·Bone Marrow Transplantation·A GratwohlUNKNOWN Accreditation Committee of the European Group for Blood and Marrow Transplantation
Apr 9, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Steven Le GouillUNKNOWN Société Française de Greffe de Moëlle et de Thérapie Cellulaire
Apr 14, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Koen van BesienParameswaran N Hari
Nov 10, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Andrea BacigalupoMary Horowitz
Feb 23, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Kitsada WudhikarnDaniel J Weisdorf
May 4, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Ron RamAjay K Gopal
Jul 31, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sonali M SmithParameswaran N Hari
Aug 7, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maximilian ChristopeitChristoph Schmid
Dec 18, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Timothy S FenskeParameswaran N Hari
Mar 19, 2014·Bone Marrow Transplantation·J R PasswegUNKNOWN European Society for Blood and Marrow Transplantation EBMT

❮ Previous
Next ❯

Citations

Jan 21, 2016·Journal of Immunology Research·Roberta FedeleFortunato Morabito
Mar 16, 2016·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Hasan Sami Göksoy, Mutlu Arat
May 24, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Nicoletta CieriJacopo Peccatori
Jan 23, 2019·Leukemia & Lymphoma·Boglarka GyurkoczaBrenda M Sandmaier
May 26, 2018·Bone Marrow Transplantation·Anna SuredaDavid L Porter
Aug 22, 2018·Chinese Medical Journal·Wen-Rong Huang, Dai-Hong Liu
Jan 10, 2020·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Peter DregerUNKNOWN European Society for Blood and Marrow Transplantation (EBMT) and the Center for International Blood and Marrow Transplant Re
Jul 1, 2020·Hematology/oncology and Stem Cell Therapy·Madiha Iqbal, Mohamed A Kharfan-Dabaja

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Related Papers

The Hematology Journal : the Official Journal of the European Haematology Association
Christelle LenainJean Yves Blay
© 2022 Meta ULC. All rights reserved